ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP81-18 Changes to Cotiviti Mailroom Operations Center Location
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါစဲးပတ့ဘၢၣ် 25, 2018
တၢ်ဃုသ့ၣ်ညါတၢ်အစၢ
တၢ်ပာ်ဖျါ 2881 - 2890 လၢ 4030 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP78-18 Pharmacy Update - Change in Coverage for Brand Serevent Diskus 50 mcg/dose
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါစဲးပတ့ဘၢၣ် 11, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP71-18 Pharmacy Benefit Update - New Drug-Related Step Therapy with Quantity Limit Criteria: Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 21, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP90-18 Addition of Drugs to the Self-Administered Oncology Agents Prior Authorization with Quantity Limit Program
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 14, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP69-18 Universal Pharmacy Policy for Minnesota Health Care Programs Subscribers - Morphine Equivalent Dose (MED) Limit Update
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 21, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP75-18 2018 Blue Cross Blue Shield MHCP Migration and New Initiatives Training
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါစဲးပတ့ဘၢၣ် 07, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP93-18 Technical Issues with Authorization and Referral Tool on Availity Resolved
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါနိၣ်၀့ဘၢၣ် 14, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP79-18 Addition of Drug to the Hereditary Angioedema Prior Authorization with Quantity Limit Program
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါစဲးပတ့ဘၢၣ် 21, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP77-18 Pharmacy Benefit Exclusion for Onpattro (patisiran) Lipid Complex Intravenous (IV) Injection
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါစဲးပတ့ဘၢၣ် 11, 2018
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP57-18 New Drug-Related Prior Authorization with Quantity Limit Criteria: Hereditary Angioedema
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 19, 2018